OXT and ovarian carcinoma: In the past five years, aberrant expression of the lncRNA SOX2-OT has been reported in some cancers, including breast cancer [13], non-small cell lung cancer [14], ovarian cancer [15], hepatocellular carcinoma [16], nasopharyngeal carcinoma [17], and glioblastoma [14].